BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 26, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Feb. 17, 2009
View Archived Issues
InterMune Prices Public Offering on Heels of Phase III IPF Data
A week after Phase III pirfenidone data in idiopathic pulmonary fibrosis sent its stock up 36 percent, InterMune Inc. decided to sell 3.5 million shares in a public offering. (BioWorld Today)
Read More
Geron Seeking $50M Plus to Support More Trials
Read More
New Tissue Engineering Path: Micro-tissues Formed in '3-D'
Read More
Stimulus Bill Allots $10B for Biomedical Research
Read More
Holiday Notice
Read More
Corrections & Clarifications
Read More
Clinic Roundup
Read More
Earnings Roundup
Read More
Other News To Note
Read More
Restructuring Roundup
Read More